GlassScriptNatpara (Parathyroid Hormone)
Payments companies reported to CMS as associated with Natpara (Parathyroid Hormone). "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Natpara (Parathyroid Hormone), per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Natpara (Parathyroid Hormone)
These are the largest totals companies reported as associated with Natpara (Parathyroid Hormone). They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| John Bilezikian | New York, NY | Endocrinology, Diabetes & Metabolism | $9,393.75 |
| Michael Mannstadt | Boston, MA | Internal Medicine | $4,567.50 |
| Michael Levine | Philadelphia, PA | Pediatric Endocrinology | $3,480.00 |
| Tamara Vokes | Chicago, IL | Endocrinology, Diabetes & Metabolism | $2,692.50 |
| Bart Clarke | Rochester, MN | Endocrinology, Diabetes & Metabolism | $1,970.00 |
| Dolores Shoback | San Francisco, CA | Internal Medicine | $1,522.50 |
Prescribed Natpara (Parathyroid Hormone)?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.